Headache Syndromes: Diagnosis and Management

Headaches are among the most common neurological complaints in clinical practice, affecting up to 90% of the population at some point in their lives. The International Classification of Headache Disorders (ICHD-3) provides a systematic approach to categorizing headaches into primary and secondary types.

Primary headaches account for approximately 90% of all headaches and include migraine, tension-type headache, and cluster headache. These disorders have no underlying structural cause and are diagnosed based on clinical criteria. Secondary headaches result from underlying pathology such as intracranial masses, infections, vascular disorders, or medication overuse.

The clinical approach to headache evaluation requires systematic assessment of headache characteristics using the mnemonic SOCRATES: Site (location), Onset (sudden vs. gradual), Character (quality of pain), Radiation, Associated symptoms, Timing (duration and frequency), Exacerbating/relieving factors, and Severity. This framework helps differentiate between headache types and identify red flags requiring urgent evaluation.

Age of onset provides important diagnostic clues. Migraine typically begins in adolescence or early adulthood, with 90% of cases starting before age 40. Tension-type headaches can begin at any age but commonly start in childhood or adolescence. Cluster headaches usually begin between ages 20-40, with a strong male predominance (3:1 ratio).

The burden of headache disorders extends beyond individual suffering to significant socioeconomic impact. Migraine alone affects over 1 billion people worldwide and is the second leading cause of disability globally. Understanding headache pathophysiology and classification enables healthcare providers to implement appropriate diagnostic strategies and targeted treatments, ultimately improving patient outcomes and quality of life.

Migraine is a complex neurovascular disorder characterized by recurrent episodes of moderate to severe headache accompanied by autonomic nervous system dysfunction. The pathophysiology involves cortical spreading depression (CSD), a wave of neuronal depolarization that propagates across the cerebral cortex at 2-6 mm/minute, followed by prolonged neuronal silencing.

Trigeminovascular activation occurs when CSD reaches the trigeminal nucleus, triggering release of vasoactive neuropeptides including calcitonin gene-related peptide (CGRP), substance P, and neurokinin A. These mediators cause neurogenic inflammation, vasodilation, and sensitization of trigeminal nociceptors, generating the characteristic throbbing pain.

Clinical phases of migraine include:

1. Prodrome (hours to days before): mood changes, food cravings, neck stiffness, fatigue
2. Aura (5-60 minutes): reversible neurological symptoms in 25% of patients
3. Headache phase (4-72 hours): unilateral, pulsating pain with associated symptoms
4. Postdrome (hours to days): fatigue, cognitive impairment, mood changes

Migraine aura manifests as visual (scintillating scotomas, fortification spectra), sensory (paresthesias), or speech disturbances. Visual auras are most common, typically beginning as small central scotomas that expand peripherally with zigzag borders. The aura develops gradually over 5+ minutes and completely resolves, distinguishing it from stroke or seizure.

Associated symptoms include nausea (90%), vomiting (30%), photophobia, phonophobia, and osmophobia. Patients typically seek quiet, dark environments and may experience allodynia (normally non-painful stimuli become painful). Triggers commonly include hormonal fluctuations, certain foods (aged cheese, alcohol), stress, sleep changes, and environmental factors.

The diagnostic criteria require at least 5 attacks lasting 4-72 hours with at least 2 pain characteristics (unilateral, pulsating, moderate-severe intensity, aggravated by activity) plus at least 1 associated symptom (nausea/vomiting or photophobia/phonophobia).

Tension-type headache (TTH) is the most prevalent primary headache disorder, affecting up to 70% of the population. Despite its frequency, the pathophysiology remains incompletely understood, likely involving peripheral nociceptive mechanisms from myofascial tissues and central sensitization in chronic forms.

Peripheral mechanisms include increased tenderness of pericranial muscles (temporalis, masseter, suboccipital, and trapezius) and myofascial trigger points. Central sensitization occurs in chronic TTH, with altered pain processing in the trigeminal nucleus caudalis and higher cortical centers, leading to decreased pain thresholds and increased pain sensitivity.

Clinical presentation features bilateral, pressing or tightening (non-pulsating) pain of mild to moderate intensity. Unlike migraine, TTH is not aggravated by routine physical activity and lacks significant associated symptoms. Patients may experience mild photophobia OR phonophobia (but not both), and nausea is typically absent.

Classification distinguishes:

• Infrequent episodic TTH: <1 day/month (<12 days/year)
• Frequent episodic TTH: 1-14 days/month (12-179 days/year) for ≥3 months
• Chronic TTH: ≥15 days/month (≥180 days/year) for ≥3 months

Risk factors include stress, anxiety, depression, poor posture, sleep disorders, and medication overuse. Women are affected twice as frequently as men, with prevalence peaking in the fourth decade of life.

Management strategies emphasize both pharmacological and non-pharmacological approaches:

Acute treatment: Simple analgesics (acetaminophen 1000 mg, ibuprofen 400-600 mg, aspirin 500-1000 mg) are first-line. Combination analgesics may be more effective but carry higher risk of medication overuse headache.

Preventive treatment is indicated for frequent episodic or chronic TTH and includes tricyclic antidepressants (amitriptyline 10-75 mg daily), which are most evidence-based. Stress management, regular sleep schedule, exercise, and cognitive behavioral therapy are important non-pharmacological interventions.

Prognosis is generally favorable for episodic forms, though chronic TTH may persist for years and significantly impact quality of life. Early intervention and comprehensive management can prevent chronification and improve outcomes.

Cluster headache is the most severe primary headache disorder, characterized by excruciating unilateral pain occurring in cyclical patterns or "clusters." The pathophysiology involves hypothalamic dysfunction, particularly in the posterior hypothalamus, which regulates circadian rhythms and explains the characteristic timing patterns.

Neuroanatomical basis includes activation of the trigeminal-autonomic reflex arc. The trigeminal ganglion projects to the trigeminal nucleus caudalis, which connects to the superior salivatory nucleus, causing parasympathetic activation via the sphenopalatine ganglion. This explains the prominent autonomic features: ipsilateral lacrimation, nasal congestion, rhinorrhea, eyelid edema, miosis, and ptosis.

Clinical presentation features:

• Pain: Strictly unilateral, severe to excruciating intensity, described as "boring" or "burning"
• Location: Orbital, supraorbital, and/or temporal regions
• Duration: 15 minutes to 3 hours (typically 30-90 minutes)
• Frequency: 1-8 attacks per day during cluster periods
• Behavior: Patients are restless and agitated, unlike migraine patients who prefer stillness

Cluster patterns include:

• Episodic: Cluster periods lasting weeks to months, separated by remission periods ≥1 month (85% of cases)
• Chronic: Attacks for >1 year without remission or with remission <1 month (15% of cases)

Demographics show strong male predominance (3-4:1), onset typically between ages 20-40, and association with smoking and alcohol consumption. Triggers during cluster periods include alcohol, strong odors, nitroglycerin, and daytime napping.

Acute treatment requires rapid-acting interventions:

• High-flow oxygen (12-15 L/min via non-rebreather mask for 15-20 minutes) - first-line, effective in 70-80%
• Subcutaneous sumatriptan 6 mg - most effective pharmacological treatment
• Intranasal sumatriptan 20 mg or zolmitriptan 5-10 mg - alternatives for needle-phobic patients

Preventive treatment is essential during cluster periods:

• Verapamil 240-480 mg daily - first-line preventive agent (requires ECG monitoring)
• Prednisone 60-80 mg daily with rapid taper - for rapid control while titrating verapamil
• Lithium 600-900 mg daily - alternative preventive, requires monitoring of levels and renal/thyroid function

Emerging treatments include CGRP antagonists, sphenopalatine ganglion stimulation, and greater occipital nerve blocks for refractory cases.

Recognition of headache red flags is crucial for identifying secondary headaches requiring urgent evaluation and treatment. The mnemonic SNOOP4 helps systematize red flag assessment: Systemic illness, Neurologic symptoms, Onset sudden, Older age, Pattern change, Positional, Precipitated by Valsalva, Papilledema.

Systemic Red Flags:

• Fever with headache: Suggests meningitis, encephalitis, or systemic infection
• Weight loss, night sweats: Malignancy or chronic infection
• HIV, immunocompromised state: Opportunistic infections, CNS lymphoma
• Pregnancy/postpartum: Preeclampsia, cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome
• Anticoagulation: Increased hemorrhage risk

Neurologic Red Flags:

• Altered consciousness: Suggests increased intracranial pressure or encephalitis
• Focal neurologic deficits: Mass lesion, stroke, or demyelinating disease
• Cognitive impairment: Normal pressure hydrocephalus, dementia, or encephalitis
• Seizures: Structural lesion or metabolic disorder
• Visual field defects: Pituitary adenoma or posterior circulation pathology

Temporal Pattern Red Flags:

• Thunderclap headache (sudden onset, peak intensity within seconds): Subarachnoid hemorrhage until proven otherwise
• First or worst headache: 11% have serious secondary cause
• Progressive worsening: Mass lesion, subdural hematoma, medication overuse
• New headache after age 50: Giant cell arteritis, mass lesion, or medication effect

Positional Red Flags:

• Worse when supine, better upright: Increased intracranial pressure
• Worse when upright, better supine: CSF leak (spontaneous or post-lumbar puncture)
• Precipitated by cough, sneeze, Valsalva: Chiari malformation, mass lesion, or increased ICP

Physical Examination Red Flags:

• Papilledema: Increased intracranial pressure
• Neck stiffness: Meningitis or subarachnoid hemorrhage
• Temporal artery tenderness: Giant cell arteritis
• Focal neurologic signs: Structural lesion

High-Risk Scenarios requiring immediate evaluation:

• Thunderclap headache with normal CT requires lumbar puncture to exclude subarachnoid hemorrhage
• Headache with fever and neck stiffness requires emergent lumbar puncture
• New headache in patients >50 years with elevated ESR/CRP suggests giant cell arteritis
• Progressive headache with papilledema requires urgent neuroimaging

Secondary headaches account for approximately 10% of all headaches but represent the most concerning scenarios requiring systematic evaluation. The diagnostic approach should be guided by clinical presentation, red flags, and pre-test probability of serious underlying pathology.

Initial Assessment Algorithm:

Headache Presentation ↓ Red Flags Present? ├─ YES → Urgent workup based on specific red flags └─ NO → Assess headache pattern and characteristics ↓ Typical primary headache pattern? ├─ YES → Treat empirically, monitor response └─ NO/Uncertain → Consider further evaluation

Neuroimaging Indications: Urgent CT/MRI:

• Thunderclap headache
• Altered mental status
• Focal neurologic deficits
• Papilledema
• Headache with fever (after LP if indicated)

Non-urgent MRI:

• Atypical headache features
• Change in established headache pattern
• New headache in patients >50 years
• Headache with aura but atypical features
• Progressive headache

Laboratory Studies: Routine labs rarely indicated for typical primary headaches. Specific indications:

• ESR/CRP: Suspected giant cell arteritis (age >50 with new headache)
• CBC: Suspected infection or malignancy
• Comprehensive metabolic panel: Suspected metabolic cause
• Thyroid function: Hyperthyroid headache
• Toxicology screen: Suspected substance-related headache

Lumbar Puncture Indications:

• Suspected meningitis/encephalitis
• Thunderclap headache with normal neuroimaging
• Suspected pseudotumor cerebri
• Suspected carcinomatous meningitis

Specific Secondary Headache Workup:

Giant Cell Arteritis (Age >50):

New headache + jaw claudication/visual symptoms ↓ ESR >50 mm/hr and/or CRP >2.45 mg/dL ↓ Urgent ophthalmology referral + high-dose steroids ↓ Temporal artery biopsy within 7-14 days

Medication Overuse Headache:

• History of frequent analgesic use (≥10 days/month for triptans, ≥15 days/month for simple analgesics)
• Headache improvement after medication withdrawal
• Requires structured detoxification program

Intracranial Hypertension:

• Opening pressure >25 cmH₂O in non-obese, >28 cmH₂O in obese patients
• Normal CSF composition
• Papilledema or sixth nerve palsy

Cervicogenic Headache:

• Unilateral headache originating from neck
• Restricted neck range of motion
• Response to diagnostic C1-3 nerve blocks

The key to successful secondary headache diagnosis lies in systematic application of clinical reasoning, appropriate use of diagnostic studies, and maintaining high suspicion for serious underlying pathology when red flags are present.

Effective headache management requires individualized treatment plans incorporating both acute and preventive strategies. The approach should consider headache type, frequency, severity, disability, and patient-specific factors including comorbidities and medication contraindications.

Acute Migraine Treatment Algorithm:

Migraine Attack ↓ Severity Assessment ├─ Mild-Moderate → NSAIDs/Acetaminophen + Antiemetic │ ├─ Response → Continue current regimen │ └─ No Response → Triptan therapy └─ Severe → Triptan + Antiemetic ├─ Response → Continue triptan └─ No Response → Consider different triptan/DHE └─ Refractory → Emergency care (IV medications)

Acute Treatment Options:

• First-line: NSAIDs (ibuprofen 400-600 mg, naproxen 500-550 mg), acetaminophen 1000 mg
• Triptans: Sumatriptan 25-100 mg, rizatriptan 5-10 mg, eletriptan 20-40 mg
• Antiemetics: Metoclopramide 10 mg, prochlorperazine 10 mg
• Combination therapy: Sumatriptan 85 mg + naproxen 500 mg

Preventive Migraine Treatment Algorithm:

Migraine Frequency ≥4 days/month OR Significant disability ↓ First-line Options: ├─ Topiramate 25-100 mg daily ├─ Propranolol 80-240 mg daily ├─ Metoprolol 100-200 mg daily └─ Amitriptyline 25-150 mg daily ↓ Inadequate response after 2-3 months ↓ Second-line Options: ├─ Valproate 500-1000 mg daily ├─ Venlafaxine XR 150 mg daily └─ Gabapentin 900-2400 mg daily ↓ Refractory cases ↓ CGRP antagonists (erenumab, fremanezumab, galcanezumab)

Tension-Type Headache Management: Episodic TTH: Simple analgesics (acetaminophen, NSAIDs) limited to <10 days/month Chronic TTH: Amitriptyline 10-75 mg daily is first-line preventive

Non-pharmacological interventions:

• Stress management and relaxation techniques
• Regular sleep schedule (7-8 hours nightly)
• Regular aerobic exercise
• Trigger identification and avoidance
• Biofeedback and cognitive behavioral therapy

Special Populations:

Pregnancy:

• Acute: Acetaminophen (pregnancy category B)
• Avoid NSAIDs after 30 weeks gestation
• Preventive: Propranolol or nortriptyline if necessary

Pediatric:

• Weight-based dosing for all medications
• Ibuprofen 10 mg/kg, acetaminophen 15 mg/kg
• Preventive: Topiramate, propranolol, or amitriptyline

Elderly:

• Start low, go slow with all medications
• Avoid anticholinergic effects (amitriptyline)
• Consider drug interactions and comorbidities

Treatment Goals:

• Reduce attack frequency by ≥50%
• Decrease attack severity and duration
• Improve functional disability
• Enhance quality of life
• Prevent medication overuse headache

Monitoring and Follow-up:

• Headache diary documentation
• Regular assessment of treatment response
• Monitoring for medication side effects
• Adjustment of therapy based on efficacy and tolerability
• Patient education regarding trigger avoidance and lifestyle modifications